Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis

This Phase I/II randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.

NCT Number	NCT07157891
Lead Sponsor	University of the Punjab Collaborators: Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.
Conditions	Osteoarthritis (OA), Knee Injury, Cartilage Degeneration
Enrollment	25 participants
Start Date	2025-12-10
Primary Completion	2027-12-11 (estimated)
Study Completion	2028-12-11 (estimated)
Updated on ClinicalTrials.gov	2025-09-05